" I’m honored to join Innate Pharma at such a pivotal moment in its evolution,”said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “ We achieved notable regul ...

ADC是肿瘤领域发展最快的治疗方式之一，目前已有15种ADC获批，超过210种正在进行临床试验。近年来，ADC的药物研发进入百花齐放阶段，特别是在HER2、EGFR、Trop2、CLDN18.2、Nectin-4等靶点上展示出显著的疗效和良好的安全性 ...

Completed Enrollment of Dose Escalation Part of Phase 1 Clinical Trial of its Next-Generation Nectin-4 Targeting ADC (CRB-701) - First data ...

Bicycle Therapeutics is a biopharma company targeting unmet medical needs. Discover why BCYC stock benefits from strong ...

Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024 ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and ...

Expands pipeline of T cell engaging bispecific antibodies through acquisitions of CT-95, a Mesothelin x CD3 bispecific ...

Corbus Pharmaceuticals still shows promise, with CRB-701 and CRB-601 advancing in clinical trials. Read why CRBP stock is ...

根据AI大模型测算迈威生物后市走势。短期趋势看，连续2日被主力资金增仓。主力没有控盘。中期趋势方面，上方有一定套牢筹码积压。近期该股获筹码青睐，且集中度渐增。舆情分析来看，2家机构预测目标均价35.00，高于当前价41.99%。目前市场情绪极度悲观。

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today ...